Loading
Loading
Research Overview
Tetrapeptide (Ala-Glu-Asp-Gly) that stimulates pineal gland melatonin secretion and activates telomerase in somatic cells, with preclinical data suggesting extension of telomere length and attenuation of age-related gene expression changes.
Epitalon (Epithalon) is a synthetic peptide that has been widely explored in preclinical research for its potential role in cellular aging and biological regulation. Derived from a naturally occurring peptide known as epithalamin—associated with the pineal gland—Epitalon consists of a short chain of amino acids and has been studied for its possible influence on molecular processes linked to longevity and cellular stability. Unlike many peptides designed purely in laboratories, Epitalon is modeled after endogenous compounds, though its full biological significance remains under active scientific investigation.
Across laboratory and animal-based models, Epitalon has been examined for its potential interaction with mechanisms related to telomeres—the protective structures at the ends of chromosomes. Research has explored whether Epitalon may influence telomerase activity, an enzyme associated with maintaining telomere length, as well as its broader role in genomic integrity and cellular replication. These studies often focus on how the peptide may interact with signaling pathways involved in aging, DNA protection, and cell cycle regulation.
In addition to its relevance in cellular aging research, Epitalon has been investigated for its potential involvement in circadian rhythm regulation and neuroendocrine signaling. Some experimental findings suggest possible interactions with the pineal gland and melatonin-related pathways, which may connect Epitalon to biological timing systems and regulatory processes governing sleep-wake cycles and hormonal balance.
To support controlled experimentation, Epitalon has been synthesized and stabilized for laboratory use, allowing researchers to examine its properties under consistent conditions. All findings referenced are derived exclusively from non-clinical studies. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, epitalon (epithalon) peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Epitalon (Epithalon) Peptide research is most relevant to protocols examining:
Telomere biology and telomerase activation research
Pineal gland and melatonin regulation studies
Longevity protocol research using cycled bioregulator approaches
Age-related gene expression and circadian rhythm investigations
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Tetrapeptide (Ala-Glu-Asp-Gly) that stimulates pineal gland melatonin secretion and activates telomerase in somatic cells, with preclinical data suggesting extension of telomere length and attenuation of age-related gene expression changes.
| Parameter | Value |
|---|---|
| Dose range | 5–10 mg/day (cycle: 10–20 days) |
| Schedule | Daily (cycled) |
| Route | Subcutaneous, Intranasal |
| Half-life | ~Hours |
Running continuously instead of cycling
Fix: standard protocol is 10–20 days on, 4–6 months off
Expecting short-term changes
Fix: telomere biology and longevity effects are long-term and cumulative
Underdosing below 5 mg/day during an active cycle
Sourcing from unverified suppliers where purity is unknown
Fix: peptide quality is critical for this compound
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
